web analytics

THC Breath Analyzer; The Story of Cannabix Technologies Inc (OTCMKTS: BLOZF)

0

Cannabix Technologies Inc (OTCMKTS: BLOZF) is making a powerful run up the charts recently surpassing $1 mark on a massive surge of volume. Microcapdaily has been covering this stock for years reporting on it well below the $0.50 mark.

BLOZF is up after the Company announced the United States Patent and Trademark Office (USPTO) has granted patent No. 14/689434 entitled, “Cannabis Drug Detection Device” to the Company. The Company and its patent attorneys have been pursuing this patent application since its filing in 2014. Cannabix Technologies is on the forefront in research and development to create point-of-care breath testing technologies for the detection of ∆9-tetrahydrocannabinol (“THC”) – the psychoactive component of marijuana that causes impairment.

Cannabix Technologies Inc (OTCMKTS: BLOZF) is a Vancouver, B.C. based technology company and the developer of a Patent Pending Cannabis Drug Detection Device. Cannabix has established breath testing technologies in the pursuit of bringing durable, portable hand-held tools to market to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many global jurisdictions. Cannabix is working to develop drug-testing devices that will detect THC- the psychoactive component of marijuana that causes intoxication- using breath samples. In particular, Cannabix is focused on developing breath testing devices for detection of recent use of THC, in contrast to urine testing for THC metabolite that requires an invasive collection and reflects usage, days or even weeks earlier. The devices will also be useful for other practical applications such as testing employees in the workplace where impairment by THC can be hazardous.

In November the Company began beta testing its version 3.0 THC Breath Analyzer (“THCBA”) in southern California with an occupational health care provider located in Newport Beach. Cannabix expects to deliver its latest version of the THCBA to Alipour Medical Centre early in the new year. Alipour Medical Centre provides drug and alcohol testing services to a number of local employers in the state. The THCBA is an ideal device for employers and other markets who are seeking a way to quickly, easily and non-invasively test for recent use of ∆9-tetrahydrocannabinol (“THC”) – the psychoactive component of marijuana that causes impairment. Cannabix will be seeking additional organizations for beta testing and welcomes interested parties to contact us via our website (cannabixtechnologies.com).

Employers everywhere are struggling with the limitations of current drug testing technology in identifying recent use of marijuana that may be causing impairment during work hours and differentiating this from recreational and medical use during nonwork hours/days. The Cannabix device allows for more relevant THC detection from breath allowing employers to create an onsite regiment whereby they can perform pre-access testing for recent use of marijuana before and during work hours, instead of testing for drug use when employees are not at work. Cannabix will be beta testing its device in order to continue training the device’s machine learning database and improve user experience through testing feedback. The THCBA has been built to provide easy to understand screen prompts for the positive and negative detection of THC in breath in a portable manner, and can be administered without extensive training.

To Find out the inside Scoop on  Cannabix Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Current forms of testing for marijuana use can identify THC ranging from minutes to days prior to actual use, making it impossible to show the difference between the two.  Studies¹ have shown that breath is a better indicator of impairment than saliva, blood, or urine because THC is present in breath for a relatively short period of time (1-3 hours); whereas, it is excreted at detectable levels in other body fluids for many hours, days, or even weeks after smoking. This short time period of detection in breath aligns with the peak impairment window.

BLOZF is up after the Company announced the United States Patent and Trademark Office (USPTO) has granted patent No. 14/689434 entitled, “Cannabis Drug Detection Device” to the Company. The Company and its patent attorneys have been pursuing this patent application since its filing in 2014. Cannabix Technologies is on the forefront in research and development to create point-of-care breath testing technologies for the detection of ∆9-tetrahydrocannabinol (“THC”) – the psychoactive component of marijuana that causes impairment.

In light of the granting of U.S. patent 14/689434, the Company undertaken a strategic review of its existing patent applications and will re-align its portfolio by canceling its second licence agreement with the University of Florida (UF) in relation to patent application 16/082,220. The Company will continue with its original licence agreement with UF in relation to patent 8,237,118. As a requirement under the licence agreement between the Company and Cannabix Breathalyzer Inc. (a separate entity) entered into on June 5th, 2014, Company will issue 5 million common shares to Cannabix Breathalyzer Inc. as a final milestone payment, triggered by the grant of patent 14/689434 by the USPTO.

“The intellectual property protection this THC detection patent covers, gives Cannabix a broad foundation to build upon in view of the formidable insights and technical advancements made in the field of molecular gas analysis at atmospheric pressure that we have developed since this patent was initially filed in 2014. Considering the field of breath detection of drugs is in its infancy, this patent is a useful step in our IP protection strategy,” said Dr. Raj Attariwala.

We have a Monster Pick Coming. Subscribe Right Now!

Cannabix Technologies Inc is making a powerful run up the charts recently surpassing $1 mark on a massive surge of volume. Microcapdaily has been covering this stock for years reporting on it well below the $0.50 mark. BLOZF is up after the Company announced the United States Patent and Trademark Office (USPTO) has granted patent No. 14/689434 entitled, “Cannabis Drug Detection Device” to the Company. The Company and its patent attorneys have been pursuing this patent application since its filing in 2014. Cannabix Technologies is on the forefront in research and development to create point-of-care breath testing technologies for the detection of ∆9-tetrahydrocannabinol (“THC”) – the psychoactive component of marijuana that causes impairment. We will be updating on Cannabix when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with Cannabix.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in Cannabix either long or short and we have not been compensated for this article.

 

Share.

Leave A Reply

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.